您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (11): 55-58.doi: 10.6040/j.issn.1671-7554.0.2015.577

• 临床医学 • 上一篇    下一篇

2型糖尿病合并下肢骨折患者凝血分子标志物的变化及其与血栓形成的关系

秦祥德1, 杨春云2, 张媛3, 倪一虹4, 于超5, 冯晓丽5, 徐成伟5   

  1. 1. 新汶矿业集团中心医院骨外科, 山东 莱芜 271219;
    2. 莱州人民医院检验科, 山东 莱州 261400;
    3. 山东大学第二医院循证医学中心, 山东 济南 250033;
    4. 山东大学第二医院内分泌科, 山东 济南 250033;
    5. 山东大学第二医院检验科, 山东 济南 250033
  • 收稿日期:2015-06-13 出版日期:2015-11-10 发布日期:2015-11-10
  • 通讯作者: 徐成伟.E-mail:xuchengwei-jyk@163.com E-mail:xuchengwei-jyk@163.com
  • 基金资助:
    山东省自然科学基金(ZR2014HM023);济南市高校自主创新计划(201303048)

Changes of thrombosis molecular markers and their clinical values in type 2 diabetic patients with low extremity fractures

QIN Xiangde1, YANG Chunyun2, ZHANG Yuan3, NI Yihong4, YU Chao5, FENG Xiaoli5, XU Chengwei5   

  1. 1. Department of Orthopedic Surgery, Central Hospital of Xinwen Mining Group, Laiwu 271219, Shandong, China;
    2. Department of Laboratory Medicine Laizhou City People s Hospital, Laizhou 261400, Shandong, China;
    3. Center of Evidence-based Medicine, Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    4. Department of Endocrinology, Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    5. Department of Laboratory Medicine, Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Received:2015-06-13 Online:2015-11-10 Published:2015-11-10

PDF (PC)

92

摘要： 目的 探讨骨折对2型糖尿病患者凝血活性的影响及其与血栓性疾病发生的关系.方法 测定2型糖尿病合并下肢骨折患者(糖尿病骨折组,n=90)、2型糖尿病患者(糖尿病组,n=90)及性别、年龄、体质量指数(BMI)均有可比性的健康人群(正常对照组,n=90)的血浆纤维蛋白原(Fib)、D-二聚体(D-dimer)、血管性血友病因子(vWF)、血小板膜颗粒糖蛋白140(GMP-140)、凝血酶原片段1+2(F1+2)、凝血酶激活的纤溶抑制物(TAFI)及组织因子途径抑制物(TFPI)等含量或活性水平,并进行组间比较.结果 糖尿病骨折组Fib、D-dimer、vWF、GMP-140、F1+2和TAFI的测定值分别为(5.3±1.4)g/L、(1 350.1±88.3)ng/mL、(161.9±6.6)IU/dL、(21.8±2.5)μg/L、(1.6±0.5)nmol/L、(30.5±3.8)μg/mL;糖尿病组的相应测定值分别为(4.1±1.2)g/L、(880.5±35.6)ng/mL、(123.6±5.5)IU/dL、(18.9±2.3)μg/L、(1.3±0.3)nmol/L、(28.3±2.9)μg/mL,正常对照组的相应测定值分别为(2.5±0.6)g/L、(145.7±22.5)ng/mL、(96.8±4.5)IU/dL、(13.8±2.1)μg/L、(0.8±0.2)nmol/L、(26.4±2.5)μg/mL,糖尿病骨折组和糖尿病组的测定值均较正常对照组显著增高(F=141.70、10 396.17、3 072.95、277.67、116.05、39.06,P<0.001),且糖尿病骨折组较糖尿病组显著增高(18.5±2.7);糖尿病骨折组和糖尿病组的血浆TFPI活性均低于正常对照组(16.2±1.3,17.3±2.1,18.5±2.7,U/mL),且糖尿病骨折组较糖尿病组更低,差异有统计学意义(F=26.68,P<0.001).结论 骨折可导致糖尿病患者的凝血活性增强,高凝状态加剧,进而易发生血栓栓塞性疾病.

关键词: 凝血分子标志物, 2型糖尿病, 血栓形成, 下肢骨折

Abstract: Objective To explore the effects of fracture on the activity of blood coagulation in patients with type 2 diabetes mellitus and the relationship between fracture and thrombotic diseases. Methods A total of 90 patients with type 2 diabetes mellitus and lower limb fracture (diabetic and fracture group), 90 patients with type 2 diabetes (diabeticgroup) and 90 healthy controls with comparable of sex, age and body mass index (control group) were recruited. The contents or activity of plasma fibrinogen (Fib), D-dimer (D-dimer), von willebrand factor (vWF), platelet membrane glycoprotein 140 (GMP-140), prothrombin fragment 1+2 (F1+2), thrombin activation of fibrinolysis inhibitor(TAFI) and tissue factor pathway inhibitor (TFPI), were compared. Results In the diabetic and facture group, the values of Fib, D-dimer, vWF, GMP-140, F1+2 and TAFI were (5.3±1.4) g/L, (1 350.1±88.3) ng/mL, (161.9±6.6) IU/dL, (21.8±2.5) μg/L, (1.6±0.5) nmol/L and (30.5±3.8) μg/mL, respectively. In the diabetic group, the values were (4.1±1.2) g/L, (880.5±35.6) ng/mL, (123.6±5.5) IU/dL, (18.9±2.3) μg/L, (1.3±0.3) nmol/L, (28.3±2.9) μg/mL, respectively. In the control group, the values were (2.5±0.6) g/L, (145.7±22.5) ng/mL, (96.8±4.5) IU/dL, (13.8±2.1) μg/L, (0.8±0.2) nmol/L, (26.4±2.5) μg/mL, respectively. The values of the former two groups were significantly higher than those of the control group, and the values of the diabetic and fracture group were higher compared to those of the diabetic group (F=141.70, 10 396.17, 3 072.95, 277.67, 116.05, 277.67, P<0.001). The plasma TFPI activity of the former two groups was lower than that of the control group (16.2±1.3, 17.3±2.1, 18.5±2.7, U/mL). And it was the lowest in the diabetic and fracture group (F=26.68, P<0.001). Conclusion Fractures can lead to blood clotting activity and high coagulation state in diabetic patients, thus such patients are prone to thromboembolic disorders.

Key words: Type 2 diabetic patients, Low extremity fractures, Coagulation molecular markers, Thrombosis

中图分类号: 

  • R446.1
[1] Morel O, Jesel L, Abbas M, et al. Prothrombotic changes in diabetes mellitus[J]. Semin Thromb Hemost, 2013, 39(5):477-488.
[2] 秦祥德, 徐成伟. 创伤性四肢骨折患者凝血纤溶指标变化[J]. 山东医药, 2010, 50(22):71-72. QIN Xiangde, XU Chengwei. Changes of coagulation and fibrinolysis indexes in patients with traumatic limbs fracture[J]. Shandong Medical Journal, 2010, 50(22):71-72.
[3] Chen SF, Xia ZL, Han JJ, et al. Increased active von Willebrand factor during disease development in the aging diabetic patient population[J]. AGE, 2013, 35(1):171-177.
[4] Ma LP, Nie DN, Hsu SX, et al. Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane b2 with pravastatin therapy for hypercholesterolemia[J]. J Assoc Acad Minor Phys, 2002, 13(1):23-26.
[5] Jax TW, Peters AJ, Plehn G, et al. Relevance of hemostatic risk factors on coronary morphology in patients with diabetes mellitus type 2[J]. Cardiovasc Diabetol, 2009, 8(24):1475-2840.
[6] Chudy P, Kotuličová D, Staško J, et al. The relationship among TAFI, t-PA, PAI-1 and F1+2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria[J]. Blood Coagul Fibrinolysis, 2011, 22(6):387-393.
[7] Chen D, Giannopoulos K, Shiels PG, et al. Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium[J]. Blood, 2004, 104(5):1344-1349. [8] Xu CW, Wu XB, Ma XL, et al. Genetic variation in thrombin- activatable fibrinolysis inhibitor (TAFI) is associated with the risk of Diabetic nephropathy[J]. J Endocrinol Invest, 2012, 35(7):620-624. [9] Xu CW, Ma XL, Zhang Y, et al. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphisms in breast cancer[J]. Blood Coagulation and Fibrinolysis, 2013, 24(7):698-703. [10] 刘延鹏, 李玲, 纪全江, 等. 非小细胞肺癌患者血浆凝血酶激活的纤溶抑制物、组织途径抑制物及凝血酶原片段1+2的水平变化及临床意义[J]. 中华检验医学杂志, 2012, 35(3):466-468. LIU Yanpeng, LI Ling, JI Quanjiang, et al. Plasma thrombin-activatable fibrinolysis inhibitor, tissue factor pathway inhibitor and fibrinopeptide 1+2 levels variation and its clinical values in patients with non-small-cell lung cancer[J]. Chinese Journal of Laboratory Medicine, 2012, 35(3):466-468. [11] 李玲, 王丽丽, 王胜江, 等. 乳腺癌患者血浆D-二聚体水平与预后关系的研究[J]. 山东大学学报:医学版, 2014, 52(9):77-80. LI Ling, WANG Lili, WANG Shengjiang, et al. Research on the relationship between plasma D-dimer level and prognosis of breast cancer patients[J]. Journal of Shandong University:Health Sciences, 2014, 52(9):77-80. [12] Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer[J]. Br J Cancer, 2002, 86(3):389-395. [13] Krupinski J, Turu MM, Font MA, et al. Increased tissue,MMP-8, and D-dimer expression in diabetic patients with unstable advanced carotid atherosclerosis[J]. Vasc Health Risk Manag, 2007, 3(4):405-412. [14] Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus[J]. Osteoporos Int, 2012, 23(2):635-641. [15] Jung JK, Kim HJ, Lee KH, et al. Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea[J]. Diabetes Metab J, 2012, 36(2):144-150.
[1] 张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7-14.
[2] 苏萍,杨亚超,杨洋,季加东,阿力木·达依木,李敏,薛付忠,刘言训. 健康管理人群2型糖尿病发病风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 82-86.
[3] 李帅,王雅琳,孙忠文,朱梅佳. Nod样受体蛋白3炎性体在2型糖尿病脑微血管内皮细胞中的变化及变化机制[J]. 山东大学学报（医学版）, 2017, 55(3): 6-11.
[4] 杨洋,张光,张成琪,宋心红,薛付忠,王萍,王丽,刘言训. 基于体检队列的2型糖尿病风险预测模型[J]. 山东大学学报（医学版）, 2016, 54(9): 69-72.
[5] 彭力,强晔,赵蕙琛,陈诗鸿,姚伟东,刘元涛. 2型糖尿病患者应用西格列汀的短期疗效及影响因素[J]. 山东大学学报（医学版）, 2016, 54(8): 60-63.
[6] 林栋,管庆波. 2型糖尿病男性患者血清睾酮水平低下对非酒精性脂肪肝的影响[J]. 山东大学学报（医学版）, 2016, 54(7): 33-37.
[7] 木哈达斯·吐尔逊依明,帕它木·莫合买提,托兰古丽·买买提库尔班. CDKAL1(rs10946398 C/A)基因多态性与2型糖尿病易感性关系Meta分析[J]. 山东大学学报（医学版）, 2016, 54(2): 75-85.
[8] 于宁,高燕燕,咸玉欣,牛佳鹏,李莉,王静,曹彩霞. 艾塞那肽对2型糖尿病合并非酒精性脂肪肝患者肝脏脂肪含量及血清chemerin水平的影响[J]. 山东大学学报（医学版）, 2016, 54(11): 51-55.
[9] 张莉,朱惠明,王艳梅,江堤,孙贤久,乐有林. 2型糖尿病患者腹胀与小肠细菌过度生长的关系[J]. 山东大学学报（医学版）, 2016, 54(1): 45-47.
[10] 刘言训, 刘佳, 张涛, 王璐, 薛付忠, 王萍. 基于纵向监测队列的2型糖尿病与甲状腺结节的关联性[J]. 山东大学学报（医学版）, 2015, 53(8): 83-86.
[11] 吴大勇, 张文艳, 房保栓, 邱刚, 边艳珠, 胡玉敬. 肺灌注SPECT/CT对不同Wells评分可疑肺栓塞的下肢深静脉血栓的诊断价值[J]. 山东大学学报（医学版）, 2015, 53(6): 86-89.
[12] 裴蕾蕾, 孙中华, 李哲, 赵文萍. 西格列汀联合大剂量胰岛素治疗2型糖尿病的临床观察[J]. 山东大学学报（医学版）, 2015, 53(2): 39-42.
[13] 胡芳志, 张正军, 耿厚法, 梁秋华, 孙琳. 2型糖尿病患者尿微量白蛋白与脑组织代谢物变化的关系[J]. 山东大学学报（医学版）, 2015, 53(2): 43-47.
[14] 李方. 可溶性晚期糖基化终末产物受体及其基因多态性与2型糖尿病的易感性分析[J]. 山东大学学报（医学版）, 2015, 53(12): 57-61.
[15] 李寒冰, 高燕燕, 李莉, 曹彩霞, 咸玉欣, 王静, 牛佳鹏. 兰索拉唑与艾塞那肽联用对2型糖尿病患者胃泌素及胃泌酸调节素的影响[J]. 山东大学学报（医学版）, 2015, 53(11): 64-68.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发